Biobijou KRX:489460KOSDAQ
바이오비쥬 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days5
DART filings, 7 days1
Articles tracked5since Sep 11
In Q2 2026, Biobijou reported revenue of ₩9.9bn, up 58.3% year on year, and operating profit of ₩2.7bn. Biobijou (바이오비쥬) appeared in 5 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Sep 11 with 5 articles. It was most often mentioned alongside Cosnine.
Biobijou quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩9.9bn | +58.3% | ₩2.7bn | ₩2.5bn |
| Q1 2026 | ₩8.0bn | -30.8% | ₩2.6bn | ₩2.9bn |
| Q4 2025 derived | ₩4.0bn | -56.4% | −₩2.7bn | −₩1.4bn |
| Q3 2025 | ₩6.6bn | -4.2% | ₩2.4bn | ₩2.4bn |
| Q2 2025 | ₩6.2bn | -11.6% | ₩1.6bn | ₩575m |
| Q1 2025 | ₩11.6bn | – | ₩2.1bn | ₩1.7bn |
| Q4 2024 derived | ₩9.2bn | – | ₩3.2bn | ₩3.4bn |
| Q3 2024 | ₩6.9bn | – | ₩2.3bn | ₩1.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Biobijou top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5